Monica A.
- Country
- France
- Department
- Medical oncology
Research Overview
- Evaluation of Preoperative Durvalumab (MEDI4736) in Patients with Early-Stage Untreated Small Triple Negative Breast Cancer
- Phase II PF-07248144 plus fulvestrant in advanced HR+/HER2- breast cancer after prior endocrine therapy and CDK4/6 inhibitor treatment
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
Data & Insights
Has run more than one trial at 285 of 601 partner sites.
Specializations
Triple-Negative Breast Cancer Research
Investigator focuses on developing treatments for locally recurrent inoperable and metastatic triple-negative breast cancer (TNBC), exploring innovative combination therapies including immunotherapy approaches.
- Advanced TNBC Treatment
- Neoadjuvant Immunotherapy
- Early-Stage TNBC Management
Hormone Receptor-Positive Breast Cancer
Specializes in treating HR-positive/HER2-negative breast cancer across various stages, investigating novel therapeutic combinations and treatment optimization strategies.
- Advanced/Metastatic Disease
- Endocrine Therapy Resistance
- Early-Stage Disease Management
Precision Medicine Applications
Pioneers the use of circulating tumor DNA (ctDNA) detection and molecular monitoring for breast cancer treatment optimization and early relapse detection.
- Molecular Relapse Detection
- Biomarker-Driven Treatment
- Treatment De-escalation Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.